Neuroscience Trials of the Future: Proceedings of a Workshop (2016)

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

A References Abbott, A. 2011. Novartis to shut brain research facility. Nature 480(7376):161- 162. Aggarwal, S. P., L. Zinman, E. Simpson, J. McKinley, K. E. Jackson, H. Pinto, R. A. Conwit, D. Schoenfeld, J. Shefner, and M. Cudkowicz. 2010. Clinical trial testing lithium in ALS terminates early for futility. Lancet Neurology 9(5):481. Alvir, J. M., J. A. Lieberman, A. Z. Safferman, J. L. Schwimmer, and J. A. Schaaf. 1993. Clozapine-induced agranulocytosis. Incidence and risk fac- tors in the United States. New England Journal of Medicine 329(3):162- 167. American Psychiatric Association. 2013. Diagnostic and statistical manual of mental disorders, 5th ed. Washington, DC: American Psychiatric Publishing. Anglemyer, A., H. T. Horvath, and L. Bero. 2014. Healthcare outcomes assessed with observational study designs compared with those assessed in random- ized trials. Cochrane Database of Systematic Reviews 4:MR000034. Arrowsmith, J., and P. Miller. 2013. Trial watch: Phase II and Phase III attrition rates 2011-2012. Nature Reviews Drug Discovery 12(8):569. Becker, R. E., and N. H. Greig. 2009. Neuropsychiatric clinical trials: Should they accommodate real-world practices or set standards for clinical practic- es? Journal of Clinical Psychopharmacology 29(1):56-64. Benson, K., and A. J. Hartz. 2000. A comparison of observational studies and randomized, controlled trials. New England Journal of Medicine 342(25):1878-1886. Berndt, E. R., and I. M. Cockburn. 2014. Price indexes for clinical trial research: A feasibility study. No. w18918. Monthly Labor Review: U.S. Bureau of Labor Statistics. Biomarkers Definitions Working Group. 2001. Biomarkers and surrogate end- points: Preferred definitions and conceptual framework. Clinical Pharma- cology & Therapeutics 69(3):89-95. 69 

70 NEUROSCIENCE TRIALS OF THE FUTURE Bleck, T., H. Cock, J. Chamberlain, J. Cloyd, J. Connor, J. Elm, N. Fountain, E. Jones, D. Lowenstein, S. Shinnar, R. Silbergleit, D. Treiman, E. Trinka, and J. Kapur. 2013. The established status epilepticus trial 2013. Epilepsia 5(s6):89-92. Borsboom, D., and A. O. Cramer. 2013. Network analysis: An integrative ap- proach to the structure of psychopathology. Annual Review of Clinical Psy- chology 9:91-121. Buckholtz, J. W., and A. Meyer-Lindenberg. 2012. Psychopathology and the human connectome: Toward a transdiagnostic model of risk for mental ill- ness. Neuron 74(6):990-1004. Button, K. S., J. P. Ioannidis, C. Mokrysz, B. A. Nosek, J. Flint, E. S. Robinson, and M. R. Munafo. 2013. Power failure: Why small sample size undermines the reliability of neuroscience. Nature Reviews Neuroscience 14(5):365- 376. Cai, N., T. B. Bigdeli, W. Kretzschmar, Y. Li, J. Liang, L. Song, J. Hu, Q. Li, W. Jin, Z. Hu, and G. Wang. 2015. Sparse whole-genome sequencing iden- tifies two loci for major depressive disorder. Nature 523(7562):588-591. Capone, M. 2015. How wearables and mobile health tech are reshaping clinical trials. Venture Beat. http://venturebeat.com/2015/04/17/how-wearables-and- mobile-health-tech-are-reshaping-clinic (accessed June 3, 2016). Casey, B. J., N. Craddock, B. N. Cuthbert, S. E. Hyman, F. S. Lee, and K. J. Ressler. 2013. DSM-5 and RDoC: Progress in psychiatry research? Nature Reviews Neuroscience 14(11):810-814. Chassang, S., E. Snowberg, B. Seymour, and C. Bowles. 2015. Accounting for behavior in treatment effects: New applications for blind trials. PLoS ONE 10(6):e0127227. Chen-Plotkin, A. S. 2014. Unbiased approaches to biomarker discovery in neu- rodegenerative diseases. Neuron 84(3):594-607. Clark, C.M., J. A. Schneider, B. J. Bedell, T. G. Beach, W. B. Bilker, M. A. Mintun, M. J. Pontecorvo, F. Hefti, A. P. Carpenter, M. L. Flitter, and M. J. Krautkramer. 2011. Use of florbetapir-PET for imaging β-amyloid patholo- gy. Journal of the American Medical Association 305(3):275-283. Cohen, P. D., L. Herman, S. Jedlinski, P. Willocks, and P. Wittekind. 2007. Eth- ical issues in clinical neuroscience research: A patient’s perspective. Neuro- therapeutics 4(3):537-544. Concato, J., N. Shah, and R. I. Horwitz. 2000. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New England Journal of Medicine 342(25):1887-1892. Connor, J. T., J. J. Elm, K. R. Broglio, ESETT, and Adapt-It Investigators. 2013. Bayesian adaptive trials offer advantages in comparative effectiveness tri- als: An example in status epilepticus. Journal of Clinical Epidemiology 66(8):S130-S137. Cook, D., D. Brown, R. Alexander, R. March, P. Morgan, G. Satter-thwaite, and M. N. Pangalos. 2014. Lessons learned from the fate of AstraZeneca’s drug 

APPENDIX A 71 pipeline: A five-dimensional framework. Nature Reviews Drug Discovery 13(6):419-431. Cross-Disorder Group of the Psychiatric Genomics Consortium. 2013. Genetic relationship between five psychiatric disorders estimated from genome- wide SNPs. Nature Genetics 45(9):984-994. Dankar, F. K., K. El Emam, A. Neisa, and T. Roffey. 2012. Estimating the re- identification risk of clinical data sets. BMC Medical Informatics and Deci- sion Making 12(1):66. Desgrousilliers, M., and G. Keet. 2015. How wearable electronics will change clinical trials. Clinical Leader. http://www.clinicalleader.com/doc/how- wearable-electronics-will-change-clinical-trials-0001 (accessed July 27, 2016). DiMasi, J. A., and H. G. Grabowski. 2007. The cost of biopharmaceutical R&D: Is biotech different? Managerial and Decision Economics 28(4-5):469-479. Dorsey, E. R., J. D. Wagner, M. T. Bull, A. Rizzieri, J. Grischkan, M. A. Achey, T. Sherer, S. Chowdhury, C. Meunier, L. Cappelletti, C. Rocker, I. H. Richard, H. Schwarz, G. Kang, S. H. Ahmad, R. A. Biemiller, and K. M. Biglan. 2015. Feasibility of virtual research visits in Fox Trial Finder. Journal of Parkinson’s Disease 5(3):505-515. Eguale, T., D. L. Buckeridge, A. Verma, N. E. Winslade, A. Benedetti, J. A. Hanley, and R. Tamblyn. 2016. Association of off-label drug use and ad- verse drug events in an adult population. Journal of the American Medical Association Internal Medicine 176(1):55-63. Ereshefsky, L., R. Evans, R. Sood, D. Williamson, and B. A. English. 2016. Venturing into a new era of CNS drug development to improve success. Waltham, MA: Parexel. https://www.parexel.com/files/4314/4113/4032/Venturing _Into_a_New_Era_of_CNS_Drug_Development_to_Improve_Success.pdf (accessed June 22, 2016). Ferrario, A., and Kanavos, P. 2015. Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agree- ments in Belgium, England, the Netherlands and Sweden. Social Science & Medicine 124:39-47. Flaherty, K. T., J. R. Infante, A. Daud, R. Gonzalez, R. F. Kefford, J. Sosman, O. Hamid, L. Schuchter, J. Cebon, N. Ibrahim, R. Kudchadkar, H. A. Burris, 3rd, G. Falchook, A. Algazi, K. Lewis, G. V. Long, I. Puzanov, P. Lebowitz, A. Singh, S. Little, P. Sun, A. Allred, D. Ouellet, K. B. Kim, K. Patel, and J. Weber. 2012. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New England Journal of Medicine 367(18):1694- 1703. Fornai, F., P. Longone, L. Cafaro, O. Kastsiuchenka, M. Ferrucci, M. L. Manca, G. Lazzeri, A. Spalloni, N. Bellio, P. Lenzi, N. Modugno, G. Siciliano, C. Isidoro, L. Murri, S. Ruggieri, and A. Paparelli. 2008. Lithium delays pro- gression of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America 105(6):2052-2057. 

72 NEUROSCIENCE TRIALS OF THE FUTURE Fournier, J. C., R. J. DeRubeis, S. D. Hollon, S. Dimidjian, J. D. Amsterdam, R. C. Shelton, and J. Fawcett. 2010. Antidepressant drug effects and depression severity: A patient-level meta-analysis. Journal of the American Medical Association 303(1):47-53. Fried, E. I., S. Epskamp, R. M. Nesse, F. Tuerlinckx, and D. Borsboom. 2016. What are “good” depression symptoms? Comparing the centrality of DSM and non-DSM symptoms of depression in a network analysis. Journal of Af- fective Disorders 189:314-320. Glickman, S.W., S. Galhenage, L. McNair, Z. Barber, K. Patel, K. A. Schulman, and J. G. McHutchison. 2012. The potential influence of Internet-based so- cial networking on the conduct of clinical research studies. Journal of Em- pirical Research on Human Research Ethics 7(1):71-80. Goodkind, M., S. B. Eickhoff, D. J. Oathes, Y. Jiang, A. Chang, L. B. Jones- Hagata, B. N. Ortega, Y. V. Zaiko, E. L. Roach, M. S. Korgaonkar, S. M. Grieve, I. Galatzer-Levy, P. T. Fox, and A. Etkin. 2015. Identification of a common neurobiological substrate for mental illness. Journal of the Ameri- can Medical Association Psychiatry 72(4):305-315. Gordon, D., W. Taddei-Peters, A. Mascette, M. Antman, P. G. Kaufmann, and M. S. Lauer. 2013. Publication of trials funded by the National Heart, Lung, and Blood Institute. New England Journal of Medicine 369(20):1926-1934. Greene, S. M., R. J. Reid, and E. B. Larson. 2012. Implementing the learning health system: From concept to action. Annals of Internal Medicine, 157(3):207-210. Gupta, S. 2012. Patient recruitment and retention are major challenges for clinical trials in CNS. Applied Clinical Trials 21(1). http://www.appliedclinicaltrials- online.com/patient-recruitment-and-retention-are-major-challenges-clinical- trials-cns (accessed July 27, 2016). GUSTO Investigators. 1993. The effects of tissue plasminogen activator, strep- tokinase, or both on coronary-artery patency, ventricular function, and sur- vival after acute myocardial infarction. The GUSTO Angiographic Investi- gators. New England Journal of Medicine 329(22):1615-1622. Haslam, N., E. Holland, and P. Kuppens. 2012. Categories versus dimensions in personality and psychopathology: A quantitative review of taxometric re- search. Psychological Medicine 42(5):903-920. Hedden, T., K. R. Van Dijk, J. A. Becker, A. Mehta, R. A. Sperling, K. A. Johnson, and R. L. Buckner. 2009. Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. The Journal of Neuroscience 29(40):12686-12694. Hernandez, A.F., C. M. O’Connor, R. C. Starling, C. J. Reist, P. W. Armstrong, K. Dickstein, T. J. Lorenz, W. B. Gibler, V. Hasselblad, M. Komajda, and B. Massie. 2009. Rationale and design of the acute study of clinical effec- tiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). American Heart Journal 157(2):271-277. 

APPENDIX A 73 Herper, M. 2015. The coming boom in brain medicines. Forbes, February 11. http://www.forbes.com/sites/matthewherper/2015/02/11/brain-boom-the-drug- companies-bringing-neuroscience-back-from-the-brink/#7247c0d352a2 (accessed June 22, 2016). Insel, T. R., and B. N. Cuthbert. 2015. Brain disorders? Precisely. Science 348(6234):499-500. IOM (Institute of Medicine). 2015. Sharing clinical trial data: Maximizing benefits, minimizing risk. Washington, DC: The National Academies Press. Kaitin, K. I. 2012. Pace of CNS drug development and FDA approvals lags oth- er drug classes. Tufts Center for the Study of Drug Development Impact Re- port 14(2). Kang, J. H., D. J. Irwin, A. S. Chen-Plotkin, A. Siderowf, C. Caspell, C. S. Coffey, T. Waligorska, P. Taylor, S. Pan, M. Frasier, K. Marek, K. Kieburtz, D. Jennings, T. Simuni, C. M. Tanner, A. Singleton, A. W. Toga, S. Chow- dhury, B. Mollenhauer, J. Q. Trojanowski, L. M. Shaw, and Parkinson’s Progression Markers Initiative. 2013. Association of cerebrospinal fluid be- ta-amyloid 1-42, T-tau, P-tau181, and alpha-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. Journal of the American Medical Association Neurology 70(10):1277-1287. Kendler, K. S. 2016. The phenomenology of major depression and the repre- sentativeness and nature of DSM criteria. American Journal of Psychiatry 173(8):771-780. Kendler, K. S., S. H. Aggen, G. P. Knudsen, E. Roysamb, M. C. Neale, and T. Reichborn-Kjennerud. 2011. The structure of genetic and environmental risk factors for syndromal and subsyndromal common DSM-IV axis I and all axis II disorders. American Journal of Psychiatry 168(1):29-39. Kesselheim, A. S., T. J. Hwang, and J. M. Franklin. 2015. Two decades of new drug development for central nervous system disorders. Nature Reviews Drug Discovery 14(12):815-816. Kumar, S., W. J. Nilsen, A. Abernethy, A. Atienza, K. Patrick, M. Pavel, W. T. Riley, A. Shar, B. Spring, D. Spruijt-Metz, D. Hedeker, V. Honavar, R. Kravitz, R. C. Lefebvre, D. C. Mohr, S. A. Murphy, C. Quinn, V. Shusterman, and D. Swendeman. 2013. Mobile health technology evaluation: The mHealth evidence workshop. American Journal of Preventative Medicine 45(2):228-236. Lahey, B. B., C. A. Van Hulle, A. L. Singh, I. D. Waldman, and P. J. Rathouz. 2011. Higher-order genetic and environmental structure of prevalent forms of child and adolescent psychopathology. Archives of General Psychiatry 68(2):181-189. Lauer, M. S., and R. B. D’Agostino, Sr. 2013. The randomized registry trial— the next disruptive technology in clinical research? New England Journal of Medicine 369(17):1579-1581. 

74 NEUROSCIENCE TRIALS OF THE FUTURE Levine, S. Z., J. Rabinowitz, R. Uher, and S. Kapur. 2015. Biomarkers of treat- ment outcome in schizophrenia: Defining a benchmark for clinical signifi- cance. European Neuropsychopharmacology 25(10):1578-1585. Lillie, E.O., B. Patay, J. Diamant, B. Issell, E. J. Topol, and N. J. Schork. 2011. The n-of-1 clinical trial: The ultimate strategy for individualizing medicine? Personalized Medicine 8(2):161-173. Liu, Q., M. Jamba, C. Patrick, III, S. Padmanabhan, and M. D. Brennan. 2012. Targeted pharmacogenetic analysis of antipsychotic response in the CATIE study. Pharmacogenomics 13(11):1227-1237. Meurer, W. J., and R. J. Lewis. 2015. Cluster randomized trials: Evaluating treatments applied to groups. Journal of the American Medical Association 313(20):2068-2069. Miller, G. 2010. Is pharma running out of brainy ideas? Science 329(5991):502- 504. Milliman, Inc. 2013. Milliman Specialty Medication Benchmark Study, 2013 analysis of 2011 data. Brookfield, WI: Millman, Inc. Montilla, S., G. Marchesini, A. Sammarco, M. P. Trotta, P. D. Siviero, C. Tomino, D. Melchiorri, L. Pani, and AIFA Anti-diabetics Monitoring Group. 2014. Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutrition, Metabolism and Cardiovas- cular Diseases 24(12):1346-1353. Montilla, S., E. Xoxi, P. Russo, A. Cicchetti, and L. Pani. 2015. Monitoring reg- istries at Italian Medicines Agency: Fostering access, guaranteeing sustain- ability. International Journal of Technology Assessment in Health Care 31(4):210-213. Nelson, M. R., H. Tipney, J. L. Painter, J. Shen, P. Nicoletti, Y. Shen, A. Flora- tos, P. C. Sham, M. J. Li, J. Wang, L. R. Cardon, J. C. Whittaker, and P. Sanseau. 2015. The support of human genetic evidence for approved drug indications. Nature Genetics 47(8):856-860. Pammolli, F., L. Magazzini, and M. Riccaboni. 2011. The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery 10(6):428-438. Pankevich, D.E., B. M. Altevogt, J. Dunlop, F. H. Gage, and S. E. Hyman. 2014. Improving and accelerating drug development for nervous system disorders. Neuron 84(3):546-553. Parekh, A., S. Buckman-Garner, S. McCune, O. Neill R, M. Geanacopoulos, S. Amur, C. Clingman, R. Barratt, M. Rocca, I. Hills, and J. Woodcock. 2015. Catalyzing the Critical Path Initiative: FDA’s progress in drug development activities. Clinical Pharmacology & Therapeutics 97(3):221-233. Prata, D., A. Mechelli, and S. Kapur. 2014. Clinically meaningful biomarkers for psychosis: A systematic and quantitative review. Neuroscience and Bio- behavioral Reviews 45:134-141. Purgato, M., C. Barbui, S. Stroup, and C. Adams. 2015. Pragmatic design in randomized controlled trials. Psychological Medicine 45(2):225-230. 

APPENDIX A 75 Qiang, J. K., Y. C. Wong, A. Siderowf, H. I. Hurtig, S. X. Xie, V. M. Lee, J. Q. Trojanowski, D. Yearout, B. Leverenz J, T. J. Montine, M. Stern, S. Mendick, D. Jennings, C. Zabetian, K. Marek, and A. S. Chen-Plotkin. 2013. Plasma apolipoprotein A1 as a biomarker for Parkinson disease. An- nals of Neurology 74(1):119-127. Ranganathan, P., C. S. Pramesh, and M. Buyse. 2015. Common pitfalls in statis- tical analysis: Clinical versus statistical significance. Perspectives in Clini- cal Research 6(3):169-170. Riordan, H., and N. Cutler. 2011. The death of CNS drug development: Over- statement or omen. Journal of Clinical Studies 3(6):12-15. Rosenthal, L. S., D. Drake, R. N. Alcalay, D. Babcock, F. D. Bowman, A. Chen- Plotkin, T. M. Dawson, R. B. Dewey, Jr., D. C. German, X. Huang, B. Landin, M. McAuliffe, V. A. Petyuk, C. R. Scherzer, C. S. Hillaire-Clarke, B. A. Sieber, M. Sutherland, C. Tarn, A. West, D. Vaillancourt, J. Zhang, K. Gwinn, on behalf of the PDBP Consortium. 2015. The NINDS Parkin- son’s disease biomarkers program. Movement Disorders 31:915-923. Rzhetsky, A., D. Wajngurt, N. Park, and T. Zheng. 2007. Probing genetic over- lap among complex human phenotypes. Proceedings of the National Acad- emy of Sciences of the United States of America 104(28):11694-11699. Sarpal, D. K., D. G. Robinson, T. Lencz, M. Argyelan, T. Ikuta, K. Karlsgodt, J. A. Gallego, J. M. Kane, P. R. Szeszko, and A. K. Malhotra. 2015. Antipsy- chotic treatment and functional connectivity of the striatum in first-episode schizophrenia. Journal of the American Medical Association Psychiatry 72(1):5-13. Sarpal, D. K., M. Argyelan, D. G. Robinson, P. R. Szeszko, K. H. Karlsgodt, M. John, N. Weissman, J. A. Gallego, J. M. Kane, T. Lencz, and A. K. Malhotra. 2016. Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. American Journal of Psychiatry 173(1):69-77. Shaw, L. M., H. Vanderstichele, M. Knapik-Czajka, C. M. Clark, P. S. Aisen, R. C. Petersen, K. Blennow, H. Soares, A. Simon, P. Lewczuk, R. Dean, E. Siemers, W. Potter, V. M. Lee, J. Q. Trojanowski, and Alzheimer’s Disease Neuroimaging Initiative. 2009. Cerebrospinal fluid biomarker signature in Alzheimer’s Disease Neuroimaging Initiative subjects. Annals of Neurology 65(4):403-413. Silberman, S. 2009. Placebos are getting more effective. Drugmakers are des- perate to know why. WIRED Magazine. http://archive.wired.com/medtech/ drugs/magazine/17-09/ff_placebo_effect?currentPage=all (accessed July 27, 2009). Slamon, D. J., G. M. Clark, S. G. Wong, W. J. Levin, A. Ullrich, and W. L. McGuire. 1987. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177- 182. Smith, I., M. Procter, R. D. Gelber, S. Guillaume, A. Feyereislova, M. Dowsett, A. Goldhirsch, M. Untch, G. Mariani, J. Baselga, M. Kaufmann, D. Cameron, 

76 NEUROSCIENCE TRIALS OF THE FUTURE R. Bell, J. Bergh, R. Coleman, A. Wardley, N. Harbeck, R. I. Lopez, P. Mallmann, K. Gelmon, N. Wilcken, E. Wist, P. Sanchez Rovira, M. J. Piccart- Gebhart, and Hera study team. 2007. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised con- trolled trial. Lancet 369(9555):29-36. Sperling, R. A., P. S. Aisen, L. A. Beckett, D. A. Bennett, S. Craft, A. M. Fagan, T. Iwatsubo, C. R. Jack, Jr., J. Kaye, T. J. Montine, D. C. Park, E. M. Reiman, C. C. Rowe, E. Siemers, Y. Stern, K. Yaffe, M. C. Carrillo, B. Thies, M. Morrison-Bogorad, M. V. Wagster, and C. H. Phelps. 2011. Toward de- fining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging‒Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia 7(3):280-292. Strom, B. L., M. Buyse, J. Hughes, and B. M. Knoppers. 2014. Data sharing, year 1—access to data from industry-sponsored clinical trials. New England Journal of Medicine 371(22):2052-2054. Swanson, C. R., Y. Berlyand, S. X. Xie, R. N. Alcalay, L. M. Chahine, and A. S. Chen-Plotkin. 2015. Plasma apolipoprotein A1 associates with age at onset and motor severity in early Parkinson’s disease patients. Movement Disor- ders 30(12):1648-1656. Taichman, D. B., J. Backus, C. Baethge, H. Bauchner, P. W. de Leeuw, J. M. Drazen, J. Fletcher, F. A. Frizelle, T. Groves, A. Haileamlak, A. James, C. Laine, L. Peiperl, A. Pinborg, P. Sahni, and S. Wu. 2016. Sharing clinical trial data: A proposal from the International Committee of Medical Journal Editors. New England Journal of Medicine 374(4):384-386. TCSDD (Tufts Center for the Study of Drug Development). 2014. Cost of devel- oping a new drug. http://csdd.tufts.edu/files/uploads/Tufts_CSDD_briefing _on_RD_cost_study_-_Nov_18,_2014.pdf (accessed June 3, 2016). TCSDD. 2015. High turnover, protocol noncompliance plaque the global site landscape. Tufts Center for the Study of Drug Development Impact Report 17(1). Tracy, H. 2015. CNS funds raised 2014. NeuroPerspective 230/231:4 Uher, R., K. E. Tansey, K. Malki, and R. H. Perlis. 2012. Biomarkers predicting treatment outcome in depression: What is clinically significant? Phar- macogenomics 13(2):233-240. U.S. National Library of Medicine. 2008. FAQ: ClinicalTrials.gov—clinical trial phases. https://www.nlm.nih.gov/services/ctphases.html (accessed June 6, 2016). Van Snellenberg, J. X., I. J. Torres, and A. E. Thornton. 2006. Functional neu- roimaging of working memory in schizophrenia: Task performance as a moderating variable. Neuropsychology 20(5):497-510. Vitiello, B. 2015. Practical clinical trials in psychopharmacology: A systematic review. Journal of Clinical Psychopharmacology 35(2):178-183. 

APPENDIX A 77 Volpi, S., S. G. Potkin, A. K. Malhotra, L. Licamele, and C. Lavedan. 2009. Applicability of a genetic signature for enhanced iloperidone efficacy in the treatment of schizophrenia. Journal of Clinical Psychiatry 70(6):801-809. Vonnegut, K. 2013. If this isn’t nice, what is?: Advice to the young. New York: Seven Stories Press. Wagle, N., C. Emery, M. F. Berger, M. J. Davis, A. Sawyer, P. Pochanard, S. M. Kehoe, C. M. Johannessen, L. E. Macconaill, W. C. Hahn, M. Meyerson, and L. A. Garraway. 2011. Dissecting therapeutic resistance to RAF inhibi- tion in melanoma by tumor genomic profiling. Journal of Clinical Oncology 29(22):3085-3096. Wallentin, L., R. C. Becker, A. Budaj, C. P. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K. W. Mahaffey, B. M. Scirica, A. Skene, P. G. Steg, R. F. Storey, R. A. Harrington, Plato Investigators, A. Freij, and M. Thorsen. 2009. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine 361(11): 1045-1057. Wan, Z., Y. Vorobeychik, W. Xia, E. W. Clayton, M. Kantarcioglu, R. Ganta, R. Heatherly, and B. A. Malin. 2015. A game theoretic framework for analyz- ing re-identification risk. PLoS ONE 10(3):e0120592. Wang, S. J., H. M. Hung, and R. O’Neill. 2011. Adaptive design clinical trials and trial logistics models in CNS drug development. European Neuropsy- chopharmacology 21(2):159-166. Wegener, G., and Rujescu, D., 2013. The current development of CNS drug research. International Journal of Neuropsychopharmacology 16(7):1687- 1693. Weiner, M. W., D. P. Veitch, P. S. Aisen, L. A. Beckett, N. J. Cairns, J. Cedar- baum, M. C. Donohue, R. C. Green, D. Harvey, C. R. Jack, Jr., W. Jagust, J. C. Morris, R. C. Petersen, A. J. Saykin, L. Shaw, P. M. Thompson, A. W. Toga, J. Q. Trojanowski, and Alzheimer’s Disease Neuroimaging Initiative. 2015. Impact of the Alzheimer’s Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer’s & Dementia 11(7):865-884. Wicks, P., T. E. Vaughan, M. P. Massagli, and J. Heywood. 2011. Accelerated clinical discovery using self-reported patient data collected online and a patient-matching algorithm. Nature Biotechnology 29(5):411-414.